NCT06302933 Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
| NCT ID | NCT06302933 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 451 participants |
| Start Date | 2024-05-02 |
| Primary Completion | 2025-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 451 participants in total. It began in 2024-05-02 with a primary completion date of 2025-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon The hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives: * Immunological aspect: lack of humoral response or immune activation * Virological aspect: Reduced HIV reservoir size * Determine the HLA phenotype in the different groups of children included and the KIR genotypes.
Eligibility Criteria
Inclusion Criteria: Case control study * Children included and followed in the ANRS 12225 study - Pediacam III * Having plasma samples in the bio bank during the above-mentioned periods Case:children with at least one negative HIV serology made by ELISA, permanent or transientduring follow-up. Control (4 groups) * HIV-infected children with positive serology and viral load (VL) \<400 copies /ml * HIV-infected children with positive serology and VL ≥400 copies / ml * HIV-uninfected children born to HIV-positive mothers * HIV-uninfected children born to HIV-uninfected mothers Selection of cases and controls will be matched on gestational age (premature \<37, term ≥37 weeks) and year of birth (2007-2008 and 2009-2010). Cross sectional study Inclusion criteria * All children still followed in the ANRS - Pediacam III cohort * Written consent of one of the parents or the guardian and assent of the child if aged ≥ 11 years and complete disclosure of HIV statusfor infected children for participation to the study. Exclusion Criteria: * Refusal by one of the parents or the guardian for the child's participation in the study * No assent of the child (if aged ≥ 11 years and with complete disclosure of HIV status, for infected children)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06302933 clinical trial?
This trial is open to participants of all sexes, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06302933 currently recruiting?
Yes, NCT06302933 is actively recruiting participants. Contact the research team at tejiokem@pasteur-yaounde.org for enrollment information.
Where is the NCT06302933 trial being conducted?
This trial is being conducted at Douala, Cameroon, Yaoundé, Cameroon, Yaoundé, Cameroon.
Who is sponsoring the NCT06302933 clinical trial?
NCT06302933 is sponsored by ANRS, Emerging Infectious Diseases. The trial plans to enroll 451 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.